Subtype
Thyroid Gland Papillary Carcinoma
CI-CAN-00006956PTCExplore in graph →
29 active trials21 evidence items
- NCIt
- C4035
- OncoTree
- THPA
- DOID
- 3969
- UMLS CUI
- C0238463
- MeSH
- D000077273
Loading cancer entity…
Subtype
CI-CAN-00006956PTCExplore in graph →
Clinical trials
158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER |
| 1 |
| Nov 24, 2025 |
| clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 17, 2026source: clinicaltrials